T-knife Therapeutics raises $110M in series B financing to push therapies to the clinic; recruits CAR T expert Peggy Sotiropoulou.
The Berlin-based company is taking aim at solid tumors with a pipeline of next-generation T-cell receptor (TCR) therapies leveraging a proprietary HuTCR transgenic mouse platform. T-knife will use the new funds to begin enrolling patients with MAGE-A1 positive cancer in the phase I/II trial IMAG1NE trial of its TCR-T cell therapy, TK-8001, later this year.
Shortly after announcing the new funds, T-knife revealed the appointment of Peggy Sotiropoulou as Chief Scientific Officer. Sotiropoulou was a tenured Research Associate Professor at the Université Libre de Bruxelles, before heading up Research & Development at Celyad Oncology, where she led the development of multiple autologous and allogeneic CAR-T drug candidates and non-gene edited allogeneic T-cell platforms. “I’m excited to join T-knife’s executive team at this pivotal moment for the company,” Sotiropoulou said in a statement. “The field of engineered cell therapy is rapidly advancing, and T-knife’s HuTCR platform has the potential to play an important role in both TCR-T and other next-generation modalities. I see great opportunity to leverage my experience, expertise and passion to contribute to T-knife’s mission of developing transformative therapies for cancer patients.”
“T-knife has an elegant and differentiated approach to identifying potent, cancer-specific TCRs with naturally optimized affinity and specificity profiles, creating a next-generation platform for this promising therapeutic field,” said Alex Mayweg, Chairman of T-knife, in a press release. “We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates.”